MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:31Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Cholesterol absorption inhibitors]]
			[[Category:Lipid-lowering agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #70

2026-05-23T03:42:09Z

parser-claude batch MedTemplate pre-fill, Top 300 #70

New page

{{MedTemplate
| generic = Ezetimibe
| brand = Zetia
| structure =
| classes = [[:Category:Cholesterol_absorption_inhibitors|Cholesterol absorption inhibitor]], [[:Category:Lipid-lowering_agents|Lipid-lowering agent]]
| uses = <vote slug="hyperlipidemia-use">Hyperlipidemia (alone or with a statin)</vote>, <vote slug="statin-intolerance-use">Statin intolerance</vote>, <vote slug="familial-hypercholesterolemia-use">Familial hypercholesterolemia (combination)</vote>, <vote slug="post-acs-secondary-prevention-use">Post-ACS secondary prevention (with statin, per IMPROVE-IT)</vote>
| starting_dose = 10 mg PO once daily, with or without food
| preparations = 10 mg tablet; also as fixed-dose combinations with simvastatin (Vytorin) and atorvastatin (Liptruzet, withdrawn US 2015 but generics exist)
| fda_max = 10 mg/d
| pill_id =
| routes = Oral
| onset = LDL lowering within 2 weeks
| duration = 24 hours
| halflife = ~22 hours (parent + active glucuronide)<ref name="zetia-label">FDA Prescribing Information, Zetia (ezetimibe), Merck/Schering, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021445s039lbl.pdf</ref>
| bioavailability = Variable (oral; rapidly conjugated to active glucuronide; food does not affect)<ref name="zetia-label" />
| pregnancy = Limited data; generally avoided particularly in combination with statin.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="ezetimibe-mech-claim">Ezetimibe binds the Niemann-Pick C1-like 1 (NPC1L1) transporter on the apical brush border of small-intestinal enterocytes, blocking the absorption of cholesterol (both dietary and biliary) without inhibiting absorption of triglycerides, fatty acids, bile acids, or fat-soluble vitamins.</vote> Reduced enterohepatic cholesterol delivery raises LDL receptor expression and lowers circulating LDL ~15-20% on top of statin. The IMPROVE-IT trial (2015) established that ezetimibe added to simvastatin improves post-ACS cardiovascular outcomes, validating the "lower LDL = better" hypothesis with a non-statin agent<ref name="zetia-label" />.
}}

== References ==
<references />

Ezetimibe - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #70